MiNK Therapeutics, Inc. 8-K

What Happened
MiNK Therapeutics (INKT) filed an 8-K (Item 5.02) announcing that Robert Kadlec, MD, resigned from the Company’s Board of Directors and all board committees effective December 29, 2025. Dr. Kadlec joined the board in October 2024 and left in connection with his acceptance of a senior U.S. government appointment as Assistant Secretary of War for Nuclear Deterrence and Chemical and Biological Defense Policy and Programs. The filing was signed by CEO Jennifer S. Buell, Ph.D., on January 2, 2026.

Key Details

• Resignation effective date: December 29, 2025.
• Director: Robert Kadlec, MD; joined MiNK’s board in October 2024.
• Reason: Accepted senior public service role — Assistant Secretary of War for Nuclear Deterrence and Chemical and Biological Defense Policy and Programs.
• Resigned from the board and all committees; filing made under Item 5.02 of Form 8-K.

Why It Matters
A board member departure can affect board expertise and governance. Dr. Kadlec brought experience in medicine, public health preparedness and national service, which the company noted as valuable. The filing does not announce a replacement or other management changes, and it contains no financial results or operational impacts. Investors should monitor future filings for any board appointments or governance updates.